Restore Vision Reports Early Clinical Signal for GPCR-Based Optogenetic Therapy in Retinitis Pigmentosa

Restore Vision Inc. has reported interim results from its ongoing first-in-human Phase 1/2 clinical trial of RV-001, an optogenetic gene therapy designed to restore vision in patients with advanced Retinitis Pigmentosa. The data, which include follow-up out to 168 days, were presented at Eyecelerator @ ARVO 2026 and the Retinal Therapeutics Innovation Summit.

Favorable safety profile in early-stage study

The open-label, dose-escalation study enrolled six patients across low- and high-dose cohorts, all of whom had no light perception at baseline. Participants received a single intravitreal injection, with safety as the primary endpoint and exploratory measures evaluating visual function.¹

No dose-limiting toxicities or treatment-related serious adverse events were reported in either cohort, supporting a favorable early safety profile.¹ These findings are consistent with broader optogenetic research, where safety has generally been manageable, but efficacy remains an area of active investigation.²

Dose-dependent improvements in visual function

Preliminary efficacy signals suggest dose-dependent improvements across multiple endpoints. In the high-dose cohort, all three patients achieved light perception or better within one month of treatment.¹ One patient demonstrated measurable chart-based visual acuity using the Berkeley Rudimentary Vision Test.¹

In the low-dose cohort, one of three patients progressed to light perception at approximately three months.¹ Improvements were further supported by concordant gains in full-field stimulus testing and functional vision assessments, including mobility and object recognition tasks.¹

The consistency across endpoints suggests the potential for biologically meaningful changes in visual function, although conclusions remain limited by the small sample size.

GPCR-based optogenetics as a next-generation approach

RV-001 delivers a chimeric rhodopsin via an adeno-associated virus (AAV) vector through intravitreal injection. The engineered protein combines the sensitivity of animal rhodopsin with the self-regenerating properties of microbial rhodopsin, aiming to enable sustained responsiveness to light.¹

The therapy activates native G-protein-coupled receptor (GPCR)-mediated phototransduction pathways, differentiating it from earlier optogenetic approaches that rely on microbial ion channels.² Those earlier methods often require high-intensity light or external devices, whereas RV-001 is designed to function under ambient light conditions without additional hardware.

Addressing unmet need in late-stage retinal disease

Retinitis pigmentosa affects approximately two million people worldwide and remains a leading inherited cause of blindness.¹ In advanced stages, patients often lose photoreceptor function entirely, limiting the applicability of traditional gene replacement therapies.³

RV-001 is mutation-agnostic, positioning it as a potential treatment option for a broad population regardless of underlying genetic mutation.¹ This represents a shift toward gene-independent approaches that aim to restore vision in late-stage disease, in which few treatment options exist.^2,3

Next steps for clinical development

Restore Vision plans to continue patient follow-up and expand data collection to further evaluate safety, durability, and efficacy across broader populations.¹ While the interim findings are encouraging, additional studies will be required to confirm whether the observed improvements translate into sustained and clinically meaningful vision restoration.

References

1. Restore Vision announces first-in-human clinical interim results for RV-001, a GPCR-based optogenetic gene therapy. (2026, May 1). PR Newswire.
   https://www.prnewswire.com/news-releases/restore-vision-announces-first-in-human-clinical-interim-results-for-rv-001-a-gpcr-based-optogenetic-gene-therapy-301XXXXX.html
    
2. Sahel, J.-A., et al. (2021, May 24). Partial recovery of visual function in a blind patient after optogenetic therapy. Nature Medicine. https://www.nature.com/articles/s41591-021-01351-4
   
   

Russell, S., et al. (2017, Aug 26). Efficacy and safety of voretigene neparvovec for RPE65-mediated inherited retinal dystrophy. The Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31868-8/fulltext